On Friday, Ensign Group earned a positive adjustment to its Relative Strength (RS) Rating, from 65 to 76.
This exclusive rating from Investor's Business Daily tracks price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Ensign Group can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Ensign Group is not currently offering a proper buying opportunity. See if the stock goes on to form a chart pattern that could kick off a new climb.
The company showed 16% EPS growth in its most recent report. Sales gains came in at 15%. The next quarterly numbers are expected on or around Apr. 24.
The company earns the No. 1 rank among its peers in the Medical-Long-Term Care industry group. Pennant Group and National Healthcare are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
